Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 6, 2005, Pages 941-946

  Kodama, Masaaki ^a   Fujioka, Toshio ^a   Murakami, Kazunari ^b   Okimoto, Tadayoshi ^a   Sato, Ryugo ^b   Watanabe, Koichiro ^b   Nasu, Masaru ^b  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Eradication; Helicobacter pylori; Immunohistochemistry; MDM2; p53

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPIC BIOPSY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH CANCER; STOMACH MUCOSA; TUMOR SUPPRESSOR GENE;

ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; GASTRIC MUCOSA; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21244455163     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03880.x     Document Type: Article

References (38)

1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; i: 1273-5.
2. Schubert TT, Bologna SD, Nensey Y, Schubert AB, Mascha EJ, Ma CK. Ulcer risk factors. Interactions between Helicobacter pylori infection, non-steroidal use, and age. Am. J. Med. 1993; 94: 413-18.
3. Maaroos HI, Kekki M, Vorobjova T, Salupere V, Sipponen P. Risk of recurrence of gastric ulcer, chronic gastritis, and grade of Helicobacter pylori colonization. A long-term follow-up study of 25 patients. Scand. J. Gastroenterol. 1994; 29: 532-6.
4. Fujioka T, Shuto R, Kodama R et al. Experimental model for chronic gastritis with Helicobacter pylori: long term follow-up study in H. pylori-infected Japanese macaques. Eur. J. Gastroenterol. Hepatol. 1993; 5 (Suppl. 1): S73-77.
5. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
6. Sakaki N, Momma K, Egawa N, Yamada Y, Kan T, Ishiwata J. The influence of Helicobacter pylori infection on the progression of gastric mucosal atrophy and occurrence of gastric cancer. Eur. J. Gastroenterol. Hepatol. 1995; 7 (Suppl. 1): S59-62.
7. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
8. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
9. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
10. Van der Hulst RW, Rauws EA, Koycu B et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-6.
11. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-5.
12. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 1991; 325: 1127-31.
13. WHO. Schistosomes, Liver Flukes and Helicobacter pylori: IARC Working Group on the Evaluation of Carcinogenic risks to Humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Scientific Publ. No. 61. Lyon: IARC, 1994; 218-20.
14. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998; 58: 4255-9.
15. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115: 642-8.
16. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-9.
17. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of china. A randomized controlled trial. JAMA 2004; 291: 187-94.
18. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
19. Barak Y, Juven T, Haffher R, Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J. 1993; 12: 461-8.
20. Momand J, Zambetti GP. MDM2: 'big brother' of p53. J. Cell. Biochem. 1997; 64: 343-52.
21. Leach FS, Tokino T, Meltzer P et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53 (Suppl.): 2231-4.
22. Leite KR, Franco MF, Srougi M et al. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. 2001; 14: 428-36.
23. Hibi K, Mitomi H, Koizumi W, Tanabe S, Saigenji K, Okayasu I. Enhanced cellular proliferation and p53 accumulation in gastric mucosa chronically infected with Helicobacter pylori. Am. J. Clin. Pathol. 1997; 108: 26-34.
24. Satoh K, Kihira K, Kawata H et al. p53 expression in the gastric mucosa before and after eradication of Helicobacter pylori. Helicobacter 2001; 6: 31-6.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
26. Hinds PW, Finlay CA, Quartin RS et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ. 1990; 1: 571-80.
27. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 1994; 54 (Suppl.): 1941S-3.
28. Tahara E, Kuniyasu H, Yasui W, Yokozaki H. Gene alterations in intestinal metaplasia and gastric cancer. Eur. J. Gastroenterol. Hepatol. 1994; 6 (Suppl.): S97-101.
29. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am. J. Pathol. 1994; 144: 511-17.
30. Murakami K, Fujioka T, Okimoto T et al. Analysis of p53 gene mutations in Helicobacter pylori-associated gastritis mucosa in endoscopic biopsy specimens. Scand. J. Gastroenterol. 1999; 34: 474-7.
31. Taniere P, Martel-Planche G, Maurici D et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am. J. Pathol. 2001; 158: 33-40.
32. Gunther T, Schneider-Stock R, Hackel C et al. MDM2 gene amplification in gastric cancer correlation with expression of MDM2 protein and p53 alterations. Mod. Pathol. 2000; 13: 621-6.
33. Aarnio M, Salovaara R, Aaltonen L, Mecklin JP, Jarvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int. J. Cancer 1997; 74: 551-5.
34. Blok P, Craanen ME, Offerhaus GJ et al. Molecular alterations in early gastric carcinomas. No apparent correlation with Helicobacter pylori status. Am. J. Clin. Pathol. 1999; 111: 241-7.
35. Suzuki H, Miyazawa M, Kai A et al. No difference in the level of gastric mucosal cell apoptosis and proliferation in Helicobacter pylori-colonized p53 heterozygous knockout mice. Aliment. Pharmacol. Ther. 2002; 16: (Suppl. 2): 158-66.
36. Fox JG, Li X, Cahill RJ et al. Hypertrophic gastropathy in Helicobacter felis-infected wild-type C57BL/6 mice and p53 hemizygous transgenic mice. Gastroenterology 1996; 110: 155-66.
37. Miyazawa M, Suzuki H, Masaoka T et al. Suppressed apoptosis in the inflamed gastric mucosa of Helicobacter pylori-colonized iNOS-knockout mice. Free Radic. Biol. Med. 2003; 34: 1621-30.
38. Suzuki H, Miyazawa M, Nagahashi S et al. Attenuated apoptosis in H. pylori-colonized gastric mucosa of Mongolian gerbils in comparison with mice. Dig. Dis. Sci. 2002; 47: 90-9.